Author: Newsdesk

PITTSBURGH, Dec. 02, 2020 (GLOBE NEWSWIRE) — II‐VI Incorporated (Nasdaq: IIVI), a leading provider of optical communications solutions for datacom and telecom networks, today announced that Dr. Sanjai Parthasarathi, Chief Marketing Officer, will be an invited speaker at ECOC, the annual European Conference on Optical Communications. The presentation will take place virtually during the Market Focus event on December 8 at 6:20 p.m. CET.

During the presentation, Dr. Parthasarathi will share the latest trends and insights on Compound Semiconductors and Engineered Materials Enabling Biomedical Optics. The ECOC Market Focus program is a focal point of the show, featuring presentations from leading experts in the fiber-optics community.

II-VI will also participate as a virtual exhibitor, December 7-9, and will showcase one of the broadest portfolios of optical communications products in the industry. Booth visitors will interact with company representatives and experience video demonstrations of these market-leading products, which are enabling the next generation of applications in datacom, telecom, and 3D sensing.

For more information about ECOC, or to register for a free visitor pass to the virtual exhibit hall and Market Focus panels, visit: www.ecocexhibition.com/register/.

About II-VI Incorporated

II-VI Incorporated, a global leader in engineered materials and optoelectronic components, is a vertically integrated manufacturing company that develops innovative products for diversified applications in communications, materials processing, aerospace & defense, semiconductor capital equipment, life sciences, consumer electronics, and automotive markets. Headquartered in Saxonburg, Pennsylvania, the Company has research and development, manufacturing, sales, service, and distribution facilities worldwide. The Company produces a wide variety of application-specific photonic and electronic materials and components, and deploys them in various forms, including integrated with advanced software to support our customers. For more information, please visit us at www.ii-vi.com.

CONTACT:

Mark Lourie Vice President, Corporate Communications [email protected] www.ii-vi.com/contact-us

Orlando, FL, Dec. 02, 2020 (GLOBE NEWSWIRE) — Sentry Management, Inc., a national leader in condominium and homeowner association management, has announced the addition of Denise Tumulty as their Vice President of Corporate Marketing. Denise will be responsible for the national marketing strategy of the company across 40 markets in 17 states, as well as internal and external communications.

“Denise brings broad marketing and branding expertise that will be a welcome addition to our leadership team as we accelerate the growth of our business and invest in top talent,” said Bradley Pomp, President of Sentry Management. “I welcome Denise to Sentry Management and am looking forward to her insights as we invest in new technology and build upon our culture of impeccable service to clients and residents across the country.”

Denise has a rich and varied background of creating successful integrated marketing campaigns, most recently as the Director of Marketing for Mount Sinai Medical Center in Miami. She started her career in Manhattan at a large media agency, negotiating and managing national TV buys and sponsorships for highly respected brands like T-Mobile. During this time, she also earned her professional MBA from Binghamton University, graduating at the top of her class. Denise’s areas of expertise include brand identity, content development, user experience, market research, and media strategy, as well as engineering lead generating social media and digital campaigns.

“I’m thrilled to join the Sentry Management team and look forward to helping accelerate continued growth throughout the nation, and reinforcing the Sentry brand as one of the nation’s top condominium and homeowner association management providers,” Denise noted.

Denise will oversee the company-wide marketing endeavors from Sentry Management’s home office in the Orlando suburb of Longwood, Florida. To learn more about Sentry Management and the regions they serve, visit SentryMgt.com.

Sentry Management is a full-service community management company. Sentry’s business is the day-to-day operation of communities, homeowner associations and condominiums. Sentry is accredited as an AMO® (Accredited Management Organization) by the Institute of Real Estate Management, providing independent evaluation that Sentry has one of the highest operating and financial standards in the industry. Sentry operates in dozens of localities in Florida, Arizona, Colorado, Connecticut, Georgia, Idaho, Iowa, Indiana, Kansas, Maryland, Missouri, New Mexico, New York, North Carolina, South Carolina, Tennessee and Virginia.

###

Attachment

• Denise Tumulty

Denise Tumulty
Sentry Management Inc.
407-788-6700
[email protected]

CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) — Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced the appointment of Tamara Joseph, J.D., L.L.M., as Chief Legal Officer, effective as of today.

“We are thrilled to welcome Tamara to Spero and look forward to benefiting from her extensive legal and leadership experience in the biotechnology space,” said Ankit Mahadevia, M.D., Chief Executive Officer of Spero Therapeutics. “This experience will be invaluable as we work to address the growing threat of multidrug-resistant bacteria through the potential commercialization of tebipenem HBr and the advancement of SPR720 and SPR206 through clinical trials.”

Ms. Joseph brings significant experience to Spero with over 20 years of leadership roles in the biotechnology sector, overseeing legal, public and government affairs, compliance and risk management. Ms. Joseph most recently served as General Counsel at Millendo Therapeutics, Inc. and previously served as General Counsel at Enzyvant Therapeutics Ltd., InVivo Therapeutics Holdings Corp., Cubist Pharmaceuticals, Inc., Mayne Pharma Ltd., and Transkaryotic Therapies, Inc. Her experience also includes establishing and leading the ex-US operations of the Biogen Idec Inc. legal and public affairs departments. Ms. Joseph received her B.A. in economics from Duke University, her J.D. from the University of Michigan Law School and her L.L.M. degrees from the College of Europe in Belgium and the University of Paris.

Ms. Joseph commented, “Joining Spero’s management team is a truly exciting opportunity. Spero’s development pipeline is impressive, and its lead asset is on a path towards regulatory approval following the announcement of positive data from the Phase 3 ADAPT-PO trial. I look forward to working with Ankit and the team as we work to advance our pipeline and transition to a commercial organization.”

In connection with Ms. Joseph joining Spero, on November 20, 2020, the Compensation Committee of Spero’s Board of Directors approved, effective as of December 2, 2020, the grant of a non-qualified stock option award to purchase 75,000 shares of its common stock to Ms. Joseph under the Spero Therapeutics, Inc. 2019 Inducement Equity Incentive Plan, as amended, or the 2019 Inducement Plan. The stock option was granted as an inducement material to Ms. Joseph becoming an employee of Spero in accordance with Nasdaq Listing Rule 5635(c)(4). The option has an exercise price equal to the closing price of Spero’s common stock on The Nasdaq Global Select Market on December 2, 2020. The option will vest over a four-year period, with 25% of the shares vesting after 12 months and the remaining shares vesting monthly over the following 36-months, subject to Ms. Joseph’s continued employment with Spero on such vesting dates. The option is subject to the terms and conditions of the 2019 Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

About Spero
Therapeutics

Spero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases.

Spero’s lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in complicated urinary tract infections (cUTI) and acute pyelonephritis (AP). In September 2020, Spero announced positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP.

Spero is also advancing SPR720, its novel oral therapy product candidate being developed for the treatment of rare, orphan pulmonary disease caused by non-tuberculous mycobacterial (NTM) infections.

Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform that is being developed to treat MDR Gram-negative infections in the hospital setting.

For more information, visit https://sperotherapeutics.com.

Forward-Looking Statements

This press release may contain forward-looking statements. These statements include, but are not limited to, statements about the initiation, timing and submission to the FDA of a NDA for tebipenem HBr and the potential approval of tebipenem HBr by the FDA; future commercialization, the potential number of patients who could be treated by tebipenem HBr and market demand for tebipenem HBr generally; expected broad access across payer channels for tebipenem HBr; the expected pricing of tebipenem HBr and the anticipated shift from IV to oral administration; the design, initiation, timing, progress and results of Spero’s preclinical studies and clinical trials and its research and development programs, including the commencement of Spero’s planned Phase 2a clinical trial of SPR720 and the commencement of Spero’s planned Phase 1 bronchoalveolar lavage (BAL) clinical trial assessing the penetration of SPR206 into the pulmonary compartment and its renal impairment study of SPR206; management’s assessment of the results of such preclinical studies and clinical trials; the direct and indirect impact of the pandemic caused by an outbreak of a new strain of coronavirus on Spero’s business and operations, including manufacturing, research and development costs, clinical trials, regulatory processes and employee expenses; and Spero’s cash forecast and anticipated expenses, anticipated payments under Spero’s agreement with Everest Medicines, potential payments under Spero’s agreement with BARDA, the sufficiency of its cash resources and the availability of additional non-dilutive funding from governmental agencies beyond any initially funded awards. In some cases, forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “aim,” “anticipate,” “could,” “intent,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including Spero’s ability to timely complete related Phase 1 trials for its planned NDA submission for tebipenem HBr, taking into account the possible effects of the COVID-19 pandemic; Spero’s need for additional funding; the lengthy, expensive, and uncertain process of clinical drug development; whether results obtained in preclinical studies and clinical trials will be indicative of results obtained in future clinical trials; Spero’s reliance on third parties to manufacture, develop, and commercialize its product candidates, if approved; the ability to develop and commercialize Spero’s product candidates, if approved; the potential impact of the COVID-19 pandemic; Spero’s ability to retain key personnel and to manage its growth; whether Spero will satisfy all of the pre-conditions to receipt of the development milestone payment under its agreement with Everest Medicines; whether BARDA elects to exercise its second option under Spero’s agreement with BARDA; whether Spero’s cash resources will be sufficient to fund its continuing operations for the periods and/or trials anticipated; and other factors discussed in the “Risk Factors” set forth in filings that Spero periodically makes with the U.S. Securities and Exchange Commission. The forward-looking statements included in this press release represent Spero’s views as of the date of this press release. Spero anticipates that subsequent events and developments will cause its views to change. However, while Spero may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Spero’s views as of any date subsequent to the date of this press release.

Spero Investor and Media Contact:

Sharon Klahre
Vice President, Investor Relations
857-242-1547
[email protected]  

MORRISVILLE, N.C., Dec. 02, 2020 (GLOBE NEWSWIRE) — Syneos Health, Inc. (Nasdaq: SYNH) (the “Company” or “Syneos Health”), the only fully integrated biopharmaceutical solutions organization combining a CRO (Contract Research Organization) and a CCO (Contract Commercial Organization), today announced the pricing of the previously announced underwritten secondary offering by affiliates of Thomas H. Lee Partners, L.P. and Advent International Corporation of an aggregate of 6,000,000 shares of the Company’s common stock (the “Offering”) at a price to the public of $61.90 per share. Syneos Health is not selling any shares and will not receive any proceeds from the proposed sale of the shares by the selling stockholders in the Offering. The Offering is expected to close on December 3, 2020, subject to customary closing conditions.

Goldman Sachs & Co. LLC and BofA Securities are acting as the underwriters of the Offering.

An automatic shelf registration statement (including a prospectus) relating to the Offering was filed with the Securities and Exchange Commission (“SEC”) on November 27, 2018 and became effective upon filing. Before you invest, you should read the registration statement, prospectus, prospectus supplement and other documents Syneos Health has made available with the SEC for information about Syneos Health and the Offering. You may obtain these documents free of charge by visiting EDGAR on the SEC website at www.sec.gov. Alternatively, copies of the prospectus and accompanying prospectus supplement, when available, may be obtained from:

Goldman Sachs & Co. LLC
Attention: Prospectus Department
200 West Street
New York, NY 10282
Telephone: +1 866 471 2526
Facsimile: +1 212 902 9316
Email: [email protected]; or

BofA Securities
NC1-004-03-43
200 North College Street, 3rd floor
Charlotte NC 28255-0001
Attn: Prospectus Department
Email: [email protected]

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

Forward-Looking Statements

Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to: reliance on key personnel; principal investigators and patients; general and international economic, political, and other risks, including currency and stock market fluctuations and the uncertain economic environment; any inability to satisfy or any failure to waive the closing conditions related to our acquisition of SHCR Holdings Corporation (“Synteract”); any failure to realize the anticipated benefits of the acquisition of Synteract; risks related to the COVID-19 pandemic; the Company’s ability to adequately price its contracts and not overrun cost estimates; any adverse effects from the Company’s customer or therapeutic area concentration; the Company’s ability to maintain or generate new business awards; the Company’s ability to increase its market share, grow its business, and execute its growth strategies; the Company’s backlog not being indicative of future revenues and its ability to realize the anticipated future revenue reflected in its backlog; fluctuations in the Company’s operating results and effective income tax rate; risks related to the Company’s information systems and cybersecurity; changes and costs of compliance with regulations related to data privacy; risks related to the United Kingdom’s withdrawal from the European Union; risks related to the Company’s transfer pricing policies; failure to perform services in accordance with contractual requirements, regulatory requirements and ethical considerations; risks relating to litigation and government investigations; risks associated with the Company’s early phase clinical facilities; insurance risk; risks of liability resulting from harm to patients; success of investments in the Company’s customers’ business or drugs; foreign currency exchange rate fluctuations; risks associated with acquired businesses, including the ability to integrate acquired operations, products, and technologies in our business; risks related to the Company’s income tax expense and tax reform; risks relating to the Company’s intellectual property; risks associated with the Company’s acquisition strategy; failure to realize the full value of goodwill and intangible assets; restructuring risk; potential violations of anti-corruption and anti-bribery laws; risks related to the Company’s dependence on third parties; downgrades of the Company’s credit ratings; competition in the biopharmaceutical services industry; changes in outsourcing trends; regulatory risks; trends in the Company’s customers’ businesses; the Company’s ability to keep pace with rapid technological change; risks related to the Company’s indebtedness; fluctuations in the Company’s financial results and stock price; and other risk factors set forth in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as updated by the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, and other SEC filings, copies of which are available free of charge on the SEC website at www.sec.gov. The Company assumes no obligation and does not intend to update these forward-looking statements, except as required by law.

About
Syneos Health

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

Investor Relations Contact: Ronnie Speight Senior Vice President, Investor Relations Phone: +1 919 745 2745 Email: [email protected]

Press/Media Contact: Danielle DeForge Vice President, External Communications Phone: +1 202 210 5992 Email: [email protected]

SAN JOSE, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) — Broadcom Inc. (NASDAQ:AVGO) announced today an industry first with Trident SmartToR (Smart Top-of-Rack), expanding the reach of merchant silicon to software-defined, fully-programmable switching, routing, and L4-L7 services at unprecedented scale. The Trident SmartToR architecture empowers a new generation of smart networking products with orders of magnitude better performance than solutions currently available in the market.

Over the last decade, merchant silicon has evolved from basic L2 switching to the world’s highest-performance switching and routing solutions. Trident SmartToR takes this to the next level with support for high-performance, advanced network services.

“Truly revolutionary, Trident SmartToR delivers unmatched performance and scale, along with merchant-silicon economics, to disrupt the L4-L7 network services market, which until now has relied on low-performing and expensive processors and FPGAs— this new offering is a true game changer,” said Ram Velaga, senior vice president and general manager, Core Switching Group, Broadcom.

Trident SmartToR enables a 100x performance increase with massive capacity: tracking 3 million connections with 3 million connection-level policies, as well as 1 million tunnels and over 1 million stateful counters for metering and telemetry.

Trident SmartToR uses a software-defined pipeline that covers switching, routing, and advanced L4-L7 network services. In addition, this pipeline enables user-defined instrumentation and analytics at the packet and connection level with nanosecond resolution. Trident SmartToR can also perform essential analytics filtering functions such as deduplication, categorization, and summarization to provide specific and actionable insights.

A leading-edge solution, Trident SmartToR also has integrated line-rate MACSec/ IPSec for pervasive security, powered by a programmable encryption engine, which maintains operational flexibility while securing network traffic.

The unparalleled breadth of Trident SmartToR’s capabilities expands its reach far beyond that of a standard top-of-rack switch, enabling merchant silicon to cover applications such as:

• Stateful L4 load balancer
• NAT/NAPT appliance with zero latency addition for new addresses
• VxLAN gateway
• High-performance DDoS attack mitigation
• High-scale, line-rate packet broker

Trident SmartToR is now shipping. Please contact Broadcom for further details. To learn more about the Broadcom Trident SmartToR click here. For more information on all Broadcom solutions please visit www.broadcom.com.

Industry Quotes

Yiqun Cai, VP of Networking, Alibaba Intelligent Cloud:

“Alibaba has had a long and successful history of collaboration with Broadcom. The new Trident SmartToR family comes with enhanced programmability, state-aware processing, and extensive table and tunnel expansion. These new SmartToR features will enable Alibaba to deliver a new generation of high-performance and high throughput data center network infrastructure.”

John McCool, Chief Platform Officer, Senior Vice President of Engineering and Operations, Arista Networks:

“The Arista 7050X and 7300X Series running EOS^® provide a best-of-breed switching for enterprise data center environments, powered by multiple generations of the Broadcom Trident architecture. We are enthusiastic about the new Trident SmartToR for an expanded set of networking roles and features such as flow state and visibility across client to cloud enterprise. Our customers continue to value the benefits of innovative merchant based silicon, versus the complexity of legacy solutions.”

Devesh Garg, CEO, Arrcus Inc.:

“We are excited to leverage the massive scale and compiler-programmable instrumentation of the new Trident SmartToR to open up new use cases. ArcOS, our network operating system solution, with unparalleled performance and low latency along with its support of advanced protocols such as SRv6, enables the new Trident SmartToR capabilities to meet customer requirements— from the data center to the 5G Edge to the multi-cloud.”

Andy Athreya, EVP and Chief Development Officer, Juniper Networks:

“Juniper Networks utilizes Trident architecture to provide higher-density and higher-performance systems for data center and campus networks. We look forward to the introduction of the Trident SmartToR family to expand the reach of our industry-leading Junos OS to deliver flexible, yet simple-to-operate solutions at scale for our cloud, service provider and enterprise customers.”
David Maltz, Technical Fellow, Microsoft:
“This new Trident device is an innovative addition to Broadcom’s switching portfolio supporting SONiC. We commend Broadcom for taking advantage of the advanced 7nm process node to deliver policy flexibility and complex packet transformations at scale expressed via extensions to SAI. This addresses high performance use cases like Appliances, Edge and 5G applications.”

Liu Zhongdong, President and CEO, Ruijie Networks:

“Ruijie is a recognized and trusted partner, delivering advanced networking solutions to the Cloud customers. The newly introduced Trident SmartToR switch silicon enables a new generation of versatile, power-optimized, and extremely high performance Cloud networking devices. Trident SmartToR enables both Ruijie and Broadcom to continue our leadership position in the Cloud market.”

Andrew Qu, Chief Network Architect, Tencent:

“Trident SmartToR provides Tencent a tremendous opportunity to consolidate our data center ToR, load balancer, NAT, firewall, and gateway appliances into a single, unified platform. This unified system design greatly reduces our R&D investment, while significantly improving our time-to-market for introduction of new technologies. Furthermore, Broadcom has solidified their 7nm leadership with a broadened portfolio to complement the existing Tomahawk4 and Trident4 products.”

About Broadcom

Broadcom Inc. (NASDAQ: AVGO) is a global technology leader that designs, develops and supplies a broad range of semiconductor and infrastructure software solutions. Broadcom’s category-leading product portfolio serves critical markets including data center, networking, enterprise software, broadband, wireless, storage and industrial. Our solutions include data center networking and storage, enterprise, mainframe and cyber security software focused on automation, monitoring and security, smartphone components, telecoms and factory automation. For more information, go to www.broadcom.com.

Broadcom, the pulse logo, Trident, Tomahawk and Connecting everything are among the trademarks of Broadcom. The term “Broadcom” refers to Broadcom Inc., and/or its subsidiaries. Other trademarks are the property of their respective owners.

Press Contact:

Jon Piazza
Corporate Communications
[email protected]
Telephone: +1 408 433 7924

• Webinar Scheduled for 11:00 AM PT/2:00 PM ET

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) — Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management will review initial results presented at the American Society of Hematology Annual Meeting from the ALLO-715 UNIVERSAL Phase 1 trial in relapsed/refractory multiple myeloma on December 5, 2020 via a live webinar at 11:00 AM Pacific Time/2:00 PM Eastern Time.

Webinar Presenters:

• David Chang, M.D., Ph.D. – President, Chief Executive Officer and Co-Founder of Allogene
• Rafael Amado, M.D. – Executive Vice President of Research & Development and Chief Medical Officer of Allogene
• Parameswaran Hari, M.D., MRCP – Chief of the Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin

Webinar

Please register for the webinar on the Company’s website at www.allogene.com under the Investors tab in the News and Events section (https://ir.allogene.com/events) or by clicking the following link directly.

The webinar will be available as a live event only and the materials presented will be available on the Allogene website prior to the start of the event.

About Allogene Therapeutics

Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies for cancer. Led by a management team with significant experience in cell therapy, Allogene is developing a pipeline of “off-the-shelf” CAR T cell therapy candidates with the goal of delivering readily available cell therapy on-demand, more reliably, and at greater scale to more patients. For more information, please visit www.allogene.com, and follow @AllogeneTx on Twitter and LinkedIn.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability to develop AlloCAR T therapies for cancer and the potential benefits of AlloCAR T therapy. Various factors may cause differences between Allogene’s expectations and actual results as discussed in greater detail in Allogene’s filings with the Securities and Exchange Commission (SEC), including without limitation in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2020. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Allogene assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

AlloCAR T™ is a trademark of Allogene Therapeutics, Inc.

Allogene Media/Investor Contact:

Christine Cassiano
Chief Communications Officer
(714) 552-0326
[email protected]

T
echnology partnership offers
h
ome care and skilled nursing
caregivers
and
employees
the ability to
access
their
personal information,
view
their paystub
s
,
and complete their continuing education all from one login
.

BERKELEY HEIGHTS, N.J., Dec. 02, 2020 (GLOBE NEWSWIRE) — Viventium, a SaaS-based human capital management (HCM) solution, and Nevvon, an innovative home and health care educational technology company, today announced their partnership. Both companies specialize in the home care and skilled nursing markets and together bring the industry’s most robust and intuitive payroll/HCM and learning management solution.

The collaboration between Viventium and Nevvon enables the two platforms to share data seamlessly. Viventium clients will now have easy single log-in access to in-service training through their already comprehensive Viventium employee self-service application. With the Nevvon and Viventium partnership, health services agencies and facilities are one step closer to reducing manual administrative efforts via an integrated platform.

“Viventium’s partnership with Nevvon could not have come at a better time. Both of our companies serve the essential health care market, requiring flexibility and state of the art communication tools for our clients’ employees who continue to work tirelessly through this pandemic,” said Dan Neuburger, Viventium CEO. “As part of our HCM suite of services, we can now offer vital on-demand education and certification training courses that will help keep caregivers, nurses, and patients safe while keeping track of this information in one integrated platform.”

The health services industry needs HCM providers that specialize in their line of work and offer unique services to address the particular challenges facing this critically important industry, such as attracting, training, and retaining the most qualified staff.

“Both of our organizations feel a deep sense of responsibility to serve our customers with the highest level of excellence,” said James Cohen, CEO of Nevvon. “We are excited to partner with Viventium in providing a meaningful experience for our joint customers.”

To learn more about Viventium, visit https://www.viventium.com. 
To learn more about Nevvon, visit https://www.nevvon.com.

About Viventium 

Viventium Software Inc. is a SaaS-based human capital management solution that provides a remarkable user experience and award-winning software. Viventium provides flexible software and expert guidance so clients can be sure their payroll is done right. 

Viventium offers specialized solutions in the health services markets which include home care agencies and skilled nursing facilities. Viventium Software supports all 50 of the United States with payroll and HR. 

For more information about Viventium, visit https://www.viventium.com, or follow @viventium on LinkedIn and Twitter. 

About Nevvon

Nevvon is a global innovative home and health care educational technology company that certifies caregivers for the mandatory annual education they earn online. Everything takes place through our simple, intuitive, and user-centric app that lets your caregivers easily educate themselves at their pace and on their schedule. Our platform simplifies and streamlines your regulatory requirements in any state so you can focus on what matters most: running a successful business.

For more information, please visit https://nevvon.com/about-us/.

Contact:
Jeff Petescia
[email protected] 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/76b7aac7-56cc-4538-a0f4-099876f62b8a

New York, Dec. 02, 2020 (GLOBE NEWSWIRE) — Grayscale Investments®, the world’s largest digital currency asset manager and sponsor of Grayscale® Ethereum Trust (OTCQX: ETHE) (the “Trust”), today announced that it has declared a 9-for-1 split (the “Share Split”) of the Trust’s issued and outstanding common units of fractional undivided beneficial interest (“Shares”). With the Share Split, shareholders of record on December 14, 2020 (the “Record Date”) will receive 8 additional Shares of the Trust for each Share held.

The Share Split will be effected on December 17, 2020 to shareholders of record as of the close of business on December 14, 2020. Following the Share Split, the Trust’s Shares will continue to be quoted on the OTCQX under the symbol “ETHE.”

Based on the Trust having 29,502,100 Shares issued and outstanding and each Share representing ownership of 0.09284789 of one Ethereum token as of the date of this press release, immediately after effectiveness of the Share Split on December 17, 2020, the Trust would have 265,518,900 Shares issued and outstanding and each Share would represent ownership of 0.01031643 of one Ethereum token.

The Trust may create new Shares after the date of this press release and up through the Record Date.

Shareholders are not required to take any action to receive the Shares in connection with the Share Split and they will not be required to surrender or exchange their Shares in the Trust. The transfer agent will automatically issue the new Shares in the Share Split.

The transfer agent for Shares of the Trust is Continental Stock Transfer & Trust Company. For questions relating to the transfer or mechanics of the Share Split, stockholders may contact Continental Stock Transfer & Trust Company, 1 State Street, 30th Floor, New York, NY 10004-1561, or by phone at: 800-509-5586 (Domestic callers) or 212-509-4000 (International callers). If Shares are held by a bank, broker or other nominee, stockholders should contact that institution directly.

Shareholders contemplating a transaction in the Trust’s Shares between the Record Date and payment date should consult a broker regarding their entitlement to the Share Split.

About Grayscale Investments® 

Grayscale Investments is the world’s largest digital currency asset manager, with more than $12.2B in assets under management as of November 30, 2020. Through its family of 10 investment products, Grayscale provides access and exposure to the digital currency asset class in the form of a security without the challenges of buying, storing, and safekeeping digital currencies directly. With a proven track record and unrivaled experience, Grayscale’s products operate within existing regulatory frameworks, creating secure and compliant exposure for investors. For more information, please visit www.grayscale.co or follow us on Twitter, @Grayscale.

[email protected]

LA JOLLA, Calif., Dec. 02, 2020 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (NASDAQ: ARTL), a clinical stage biopharmaceutical company focused on the development of therapeutics that modulate endogenous signaling pathways, including the endocannabinoid system, today announced the appointment of drug discovery and development veteran Gregory R. Reyes, M.D., Ph.D. to the Company’s Board of Directors, effective November 30, 2020. 

“Dr. Reyes’ expert role and track record in taking small molecules and biologics through the development process make him an ideal addition for the next phase of Artelo’s advancement,” commented Connie Matsui, chairperson of Artelo’s Board of Directors.  “We are grateful and excited to welcome him to the Board.” 

Dr. Reyes brings 35 years of experience in biotech and large pharma to Artelo. Currently he is co-founder and Board member of San Diego-based Orox Biosciences. Previously, he was Senior Vice President, Drug Discovery & Site Head at Celgene San Diego, led the Oncology franchise at Biogen Idec, headed Discovery Biology at the Pfizer Ann Arbor campus, and oversaw Tumor Biology and Infectious Diseases at Schering-Plough Research Institute. Over the course of his career, Dr. Reyes and his teams advanced more than 50 small molecules and biologics from discovery into preclinical and clinical development.  One of these was Merck’s (Schering-Plough) Victrelis™ (boceprevir) which was approved as one of the first small molecule antiviral treatments for chronic hepatitis C and which received the 2012 Prix Galien Award along with Vertex’s Incivek™ as the ‘best pharmaceutical agent’ in both the UK and US. 

“As a young company, Artelo has demonstrated impressive versatility and progress in identifying and developing potentially transformative treatments in cancer, anorexia, and anxiety disorders,” added Dr. Reyes. “I’m looking forward to joining this seasoned team and providing guidance for the growth and development of the company and its product candidates.” 

Dr. Reyes obtained his M.D. and Ph.D. degrees through the Medical Scientist Training Program at The Johns Hopkins School of Medicine.  He completed his medical and postdoctoral training at Stanford University Hospital, where he was awarded a Damon Runyon Cancer Research Fellowship for studies at Stanford’s Cancer Biology Research Lab.  He has nearly 100 scientific publications and 50 US and foreign patents and applications. Dr. Reyes currently serves as advisor to Cancer Research UK’s New Agents Committee and previously served on NIH’s National Advisory General Medical Sciences Council, and the Standing Review Committee for the Research Centers in Minority Institutions, National Center for Research Resources. 

About Artelo Biosciences

Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting endogenous signaling pathways including the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, PTSD, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.

Forward Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

Investor Relations Contact:

Crescendo Communications, LLC
Tel: 212-671-1020
Email: [email protected] 

NEW YORK, Dec. 02, 2020 (GLOBE NEWSWIRE) — Sequential Brands Group, Inc. (“Sequential” or the “Company”) (NASDAQ:SQBG) today announced that its Board of Directors has relaunched a broad exploration of strategic alternatives available to the Company to best position it for success and maximize value. Such strategic alternatives may include the sale of the Company or the divestiture of one or more existing brands. Stifel is the exclusive financial advisor for the process. “The Company has successfully rationalized its cost structure and strengthened its relationships with key stakeholders during the past several months. We believe now is the right time to re-focus on the process of exploring strategic alternatives to fully maximize value for our shareholders,” said William Sweedler, Executive Chairman of Sequential.

About Sequential Brands Group, Inc.

Sequential Brands Group, Inc. (Nasdaq: SQBG) owns, promotes, markets, and licenses a portfolio of consumer brands in the active and lifestyle categories. Sequential seeks to ensure that its brands continue to thrive and grow by employing strong brand management, and marketing teams. Sequential has licensed and intends to license its brands in a variety of consumer categories to retailers, wholesalers and distributors in the United States and around the world. For more information, please visit Sequential’s website at: www.sequentialbrandsgroup.com. To inquire about licensing opportunities, please email: [email protected].

Forward-Looking Statements

Certain statements in this press release and oral statements made from time to time by representatives of the Company are forward-looking statements (“forward-looking statements”) within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date hereof and are based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management. The Company’s actual results or actual events could differ materially from those stated or implied in forward-looking statements. Forward-looking statements include statements concerning estimates of GAAP net income, non-GAAP net income, Adjusted EBITDA, revenue (including guaranteed minimum royalties), and margins, guidance, plans, objectives, goals, strategies, expectations, intentions, projections, developments, future events, performance or products, underlying assumptions and other statements that are not historical in nature, including those that include the words “subject to,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “estimates,” “forecasts,” “projects,” “aims,” “targets,” “may,” “will,” “should,” “can,” “future,” “seek,” “could,” “predict,” the negatives thereof, variations thereon and similar expressions. Such forward-looking statements reflect the Company’s current views with respect to future events, based on what the Company believes are reasonable assumptions. Whether actual results will conform to expectations and predictions is subject to known and unknown risks and uncertainties, including: (i) risks and uncertainties discussed in the reports that the Company has filed with the Securities and Exchange Commission (the “SEC”); (ii) general economic, market or business conditions; (iii) the Company’s ability to identify suitable targets for acquisitions and to obtain financing for such acquisitions on commercially reasonable terms; (iv) the Company’s ability to timely achieve the anticipated results of any potential future acquisitions; (v) the Company’s ability to successfully integrate acquisitions into its ongoing business; (vi) the potential impact of the consummation any potential future acquisitions on the Company’s relationships, including with employees, licensees, customers and competitors; (vii) the Company’s ability to achieve and/or manage growth and to meet target metrics associated with such growth; (viii) the Company’s ability to successfully attract new brands and to identify suitable licensees for its existing and newly acquired brands; (ix) the Company’s substantial level of indebtedness, including the possibility that such indebtedness and related restrictive covenants may adversely affect the Company’s future cash flows, results of operations and financial condition and decrease its operating flexibility; (x) the Company’s ability to achieve its guidance; (xi) continued market acceptance of the Company’s brands; (xii) changes in the Company’s competitive position or competitive actions by other companies; (xiii) licensees’ ability to fulfill their financial obligations to the Company; (xiv) concentrations of the Company’s licensing revenues with a limited number of licensees and retail partners; (xv) uncertainties related to the timing, proposals or decisions arising from the Company’s strategic review, including the divestiture of one or more existing brands or a sale of the Company; (xvi) adverse effects on the Company and its licensees due to natural disasters, pandemic disease and other unexpected events; (xvii) uncertainties around the effects of the COVID-19 pandemic, including adverse effects on the Company’s business, financial position, cash flows, ability to comply with its debt covenants and related uncertainty around the Company’s ability to continue as a going concern; and (xviii) other circumstances beyond the Company’s control. Refer to the section entitled “Risk Factors” set forth in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q for a discussion of important risks, uncertainties and other factors that may affect the Company’s business, results of operations and financial condition. In addition, the global economic climate and additional or unforeseen effects from the COVID-19 pandemic amplify many of the foregoing risks. The Company’s stockholders are urged to consider such risks, uncertainties and factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. Forward-looking statements are not, and should not be relied upon as, a guarantee of future performance or results, nor will they necessarily prove to be accurate indications of the times at or by which any such performance or results will be achieved. As a result, actual outcomes and results may differ materially from those expressed in forward-looking statements. The Company is not under any obligation to, and expressly disclaims any such obligation to, update or alter its forward-looking statements, whether as a result of new information, future events or otherwise. Readers should understand that it is not possible to predict or identify all risks and uncertainties to which the Company may be subject. Consequently, readers should not consider such disclosures to be a complete discussion of all potential risks or uncertainties. 

For Media and Investor Relations inquiries, contact:

Sequential Brands Group, Inc.

Katherine Nash
T: +1 512-757-2566
E: [email protected]